Drug
MK 3120
MK 3120: highest development phase Phase 1/2, developed by Merck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK-3120 NCT06818643 | Phase 1/2 | Advanced Solid Tumors |
| MK-3120 NCT07222488 | Phase 1/2 | Bladder Cancer |
Latest
No recent events.
Follow MK 3120 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.